ImmunityBio, Inc. (IBRX)
10.51
+0.60
(+6.05%)
USD |
NASDAQ |
Oct 09, 16:00
10.54
+0.03
(+0.29%)
After-Hours: 06:05
ImmunityBio Free Cash Flow (Quarterly) : -70.03M for June 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -70.03M |
| March 31, 2026 | -77.15M |
| December 31, 2025 | -71.65M |
| September 30, 2025 | -69.68M |
| June 30, 2025 | -80.83M |
| March 31, 2025 | -87.03M |
| December 31, 2024 | -87.26M |
| September 30, 2024 | -101.56M |
| June 30, 2024 | -101.07M |
| March 31, 2024 | -108.25M |
| December 31, 2023 | -123.23M |
| September 30, 2023 | -93.08M |
| June 30, 2023 | -88.30M |
| March 31, 2023 | -92.74M |
| December 31, 2022 | -109.66M |
| September 30, 2022 | -96.54M |
| June 30, 2022 | -107.20M |
| March 31, 2022 | -123.51M |
| December 31, 2021 | -82.04M |
| September 30, 2021 | -80.75M |
| June 30, 2021 | -77.64M |
| March 31, 2021 | -67.55M |
| December 31, 2020 | -23.46M |
| September 30, 2020 | -19.98M |
| Date | Value |
|---|---|
| June 30, 2020 | -16.92M |
| March 31, 2020 | -12.74M |
| December 31, 2019 | -15.56M |
| September 30, 2019 | -16.98M |
| June 30, 2019 | -17.81M |
| March 31, 2019 | -15.18M |
| December 31, 2018 | -16.08M |
| September 30, 2018 | -21.23M |
| June 30, 2018 | -18.76M |
| March 31, 2018 | -20.41M |
| December 31, 2017 | -25.07M |
| September 30, 2017 | -20.85M |
| June 30, 2017 | -23.11M |
| March 31, 2017 | -14.57M |
| December 31, 2016 | -12.11M |
| September 30, 2016 | -13.76M |
| June 30, 2016 | -9.357M |
| March 31, 2016 | -9.923M |
| December 31, 2015 | -11.90M |
| September 30, 2015 | -4.85M |
| June 30, 2015 | -8.806M |
| March 31, 2015 | -1.991M |
| December 31, 2014 | |
| March 31, 2014 | -0.258M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| Moderna, Inc. | -563.00M |
| Sarepta Therapeutics, Inc. | 196.52M |
| Arrowhead Pharmaceuticals, Inc. | -181.32M |
| Oncolytics Biotech, Inc. | -8.066M |
| Sangamo Therapeutics, Inc. | -19.30M |